The metabolic and cytoprotective orientation of meldonium in multimorbidity

DOI: https://doi.org/10.29296/25877305-2022-04-08
Issue: 
4
Year: 
2022

Professor V. Larina, MD; D. Karpenko, Candidate of Medical Sciences
N.I. Pirogov Russian National Research Medical University, Ministry of Health
of Russia, Moscow

The paper discusses the vaso-, neuro- and cardioprotective effects of a cytoprotective drug from a class of partial inhibitors of fatty acid β-oxidation (meldonium) and the possibility of its use in patients with multimorbidity. Meldonium is currently recommended for use as part of combination therapy for a number of cardiovascular diseases as a cytoprotector that affects cellular energy metabolism during ischemia and improves the use of oxygen by cells, including cardiomyocytes. Meldonium has a good safety and tolerability profile, increases exercise tolerance, performance in patients with coronary heart disease, stable exertional angina, heart failure, and improves quality of life. The additional immunomodulatory effects of meldonium allow the use of this drug to be expanded in clinical practice. The authors present their own observation of a middle-aged female patient with concomitant diseases who has taken meldonium as part of combination pathogenetic therapy. The paper discusses the possibilities of using meldonium that affects the neurometabolic processes in order to enhance the efficiency of therapy, to reduce the manifestations of asthenic syndrome, and to improve quality of life in the patients.
Keywords: 
therapy
multimorbidity
quality of life
meldonium
cytoprotection

References: 
  1. Stable coronary heart disease. Clinical guidelines 2020. Russian Journal of Cardiology. 2020; 25 (11): 4076 (in Russ.). DOI:10.15829/1560-4071-2020-4076
  2. Kobalava J.D., Conradi A.O., Nedogoda S.V. et al. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020; 25 (3): 3786 (in Russ.). DOI: 10.15829/1560-4071-2020-3-3786
  3. Chronic heart failure. Clinical guidelines 2020. Russian Journal of Cardiology. 2020; 25 (11): 4083 (in Russ.). DOI: 10.15829/1560-4071-2020-4083
  4. Roth G., Johnson C., Abajobir A. et al. Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015. J Am Coll Cardiol. 2017; 70 (4): 1–25. DOI: 10.1016/j.jacc.2017.04.052
  5. Oganov R.G., Simanenkov V.I., Bakulin I.G. et al. Comorbidities in clinical practice. Algorithms for diagnostics and treatment. Cardiovascular Therapy and Prevention. 2019; 18 (1): 5–66 (in Russ.). DOI: 10.15829/1728-8800-2019-1-5-66
  6. Bokeria A.L., Golukhova E.Z., Popov S.V. et al. Supraventricular tachycardias in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2021; 26 (5): 4484 (in Russ.). DOI: 10.15829/1560-4071-2021-4484
  7. Dedov D.V., Ivanov A.P., Elgardt I.A. Effect of electromechanical remodeling of the heart on the development of atrial fibrillation in patients with CHD and arterial hypertension. Russian Journal of Cardiology. 2011;. 16(4): 13–8 (in Russ.).
  8. Salive M.E. Multimorbidity in older adults. Epidemiol Rev. 2013; 35: 75–83. DOI: 10.1093/epirev/mxs009
  9. Johnston M.C., Crilly M., Black C. et al. Defining and measuring multimorbidity: a systematic review of systematic reviews. Eur J Public Health. 2019; 29 (1): 182–9. DOI: 10.1093/eurpub/cky098
  10. Dedov D.V., Ivanov A.P., Elgardt I.A. Risk of relapse of atrial fibrillation in patients with coronary artery disease and arterial hypertension according to the data of the ECG holter monitoring. Journal of Arrhythmology. 2010; 59 (59): 27–32 (in Russ.).
  11. Dedov D.V., Elgardt I.A., Ryazanova S. V. et al. Quality of life of CHD patients after percutaneous coronary interventions. Preventive Medicine. 2014; 17 (2-2): 23 (in Russ.).
  12. Dedov D., Mukailov N., Yevtyukhin I. Medicines with potassium and magnesium in complex prevention of complications with patients with AH and IHD. Vrach. 2013; 8: 45–6 (in Russ.).
  13. Kernick D., Chew-Graham C.A., O’Flynn N. Clinical assessment and management of multimorbidity: NICE guideline. Br J Gen Pract. 2017; 67 (658): 235–6. DOI: 10.3399/bjgp17X690857
  14. Statsenko M.Ye., Turkina S.V., Tyshchenko I.A. et al. Application of Mildronate® in patients with comorbidity: focus on cardioneurology. Therapy. 2016; 5 (9): 14–22 (in Russ.).
  15. Ginsberg M.D. Neuroprotection for ischemic stroke: past, present and future. Neuropharmacology. 2008; 55 (3): 363–89. DOI: 10.1016/j.neuropharm.2007.12.007
  16. Dambrova M., Makrecka-Kuka M., Vilskersts R. et al. Pharmacological Effects of Meldonium: Biochemical Mechanisms and Biomarkers of Cardiometabolic Activity. Pharmacol Res. 2016; 113: 771–80. DOI: 10.1016/j.phrs.2016.01.019
  17. El-Hattab A.W., Scaglia F. Disorders of carnitine biosynthesis and transport. Mol Genet Metab. 2015; 116 (3): 107–12. DOI: 10.1016/j.ymgme.2015.09.004
  18. Speijer D., Manjeri G.R., Szklarczyk R. How to Deal with Oxygen Radicals Stemming from Mitochondrial Fatty Acid Oxidation. Philos Trans R Soc Lond Biol Sci. 2014; 369 (1646): 20130446. DOI: 10.1098/rstb.2013.0446
  19. Smeitink J., van den Heuvel L., DiMauro S. The genetics and pathology of oxidative phosphorylation. Nat Rev Genet. 2001; 2: 342–52. DOI: 10.1038/35072063
  20. Lindquist C., Bjørndal B., Rossmann C.R. et al. A fatty acid analogue targeting mitochondria exerts a plasma triacylglycerol lowering effect in rats with impaired carnitine biosynthesis. PLoS One. 2018; 13 (3): e0194978. DOI: 10.1371/journal.pone.0194978
  21. Statsenko M.E., Turkina S.V., Lopushkova Yu.E. New data on well-known drug: focus on meldonium. Meditsinskiy sovet = Medical Council. 2021; 14: 110–7 (in Russ.). DOI: 10.21518/2079-701X-2021-14-110-117
  22. Vilnis D., Pozdnyakov Yu.M. Effectiveness of Mildronate®, combined with standard therapy, in the angina pectoris treatment. Cardiovascular Therapy and Prevention. 2011; 10 (6): 138–9 (in Russ.).
  23. Firsov A.A., Smirnov M.V. Effectiveness of cytoprotective therapy in stroke. The Russian Archives of Internal Medicine. 2011;(2):39–43 (in Russ.). DOI: 10.20514/2226-6704-2011-0-2-39-43
  24. Statsenko M.E., Nedogoda S.V., Turkina S.V. et al. Mildronate potential for correcting cognitive dysfunction in elderly patients with arterial hypertension. Russian Journal of Cardiology. 2011; 4: 91–5 (in Russ.).
  25. Shevtsova V.A., Vertkin A.L. Experience with the use of meldonium in long immobilized patients with cerebrovascular diseases. Ambulatornyi priem. 2015; 1 (1): 23–6 (in Russ.).
  26. Vertkin A.L., Sycheva A.S., Kebina A.L. et al. Metabolic Support Opportunities in Coronavirus Infection. Terapiya = Therapy. 2020; 7: 146–55 (in Russ.). DOI: 10.18565/therapy.2020.7.146-155
  27. Nedogoda S.V. Meldonium as a supernosological drug. Consilium Medicum. 2020 22 (5): 57–61 (in Russ.). DOI: 10.26442/20751753.2020.5.200208
  28. Dedov D.V., Mazaev V.P., Ryazanova S.V. et al. Study of quality of life in interventional and conservative treatment of patients with stable angina pectoris at remote follow-up. Cardiovascular therapy and prevention. 2014; 13 (5): 31–5. DOI: 10.15829/1728-8800-2014-5-31-35
  29. Knuuti J., Wijns W., Saraste A. et al. ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020; 41 (3): 407–77. DOI: 10.1093/eurheartj/ehz425